Karam Mazin Gharab, Mohammad Ahmad Bik, Safaa Ehssan Atta, Ghufran S Jawad, Eissa Almaghrebi, Isam Noori Salman, AIi Unlu
{"title":"评价胸腺素α原、三甲胺- n -氧化物和缺血修饰白蛋白在2型糖尿病患者血脂异常中的作用。","authors":"Karam Mazin Gharab, Mohammad Ahmad Bik, Safaa Ehssan Atta, Ghufran S Jawad, Eissa Almaghrebi, Isam Noori Salman, AIi Unlu","doi":"10.5339/qmj.2025.39","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Prothymosin alpha (PTMα) is a small acidic polypeptide from the thymosin family with immune activity and protective properties against oxidative stress induced by reactive oxygen species trimethylamine-N-oxide (TMAO), produced in the liver from gut bacterial metabolite trimethylamine and associated with increased cardiovascular disease risk and higher all-cause mortality. Ischemia-modified albumin (IMA) is a significant oxidative stress biomarker, particularly in ischemia-reperfusion conditions. This study investigates PTMα, TMAO, and IMA levels in type 2 diabetes mellitus (T2DM) patients, both with and without hyperlipidemia, to explore their relationships and their potential role as biomarkers or therapeutic targets. <b>Method:</b> The study received ethical approval from the Selcuk University Faculty of Medicine Hospital committee under approval number 2024/33. The study included male and female T2DM patients aged 30-60, with 30 having hyperlipidemia and the rest being non-lipemic. TMAO was performed using API 3200 LC-MS\\MS while PTMα was analyzed using an ELISA kit from BT LAB, serum IMA levels were evaluated by the spectrophotometric method. <b>Results:</b> Comparisons were made between those with T2DM and control groups. In the T2DM group, PTMα was significantly higher in females (<i>p</i> = 0.047), while TMAO and IMA showed no significant gender difference. The control group had no significant differences in PTMα, TMAO, and IMA levels. Comparisons among healthy controls, non-lipemic T2DM patients, and hyperlipidemic T2DM patients revealed significantly decreased PTMα levels with no change in IMA levels across groups. In contrast, TMAO was significantly higher in the patient group. <b>Conclusion:</b> The findings of this study have potential implications for the field, suggesting that PTMα might serve as a prognostic indicator for T2DM and that reduced TMAO levels might play a role in T2DM pathogenesis, opening up new avenues for research and treatment.</p>","PeriodicalId":53667,"journal":{"name":"Qatar Medical Journal","volume":"2025 2","pages":"39"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337776/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of prothymosin alpha, trimethylamine-N-oxide, and ischemia-modified albumin in type 2 diabetes mellitus patients with dysregulated lipid profile.\",\"authors\":\"Karam Mazin Gharab, Mohammad Ahmad Bik, Safaa Ehssan Atta, Ghufran S Jawad, Eissa Almaghrebi, Isam Noori Salman, AIi Unlu\",\"doi\":\"10.5339/qmj.2025.39\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Prothymosin alpha (PTMα) is a small acidic polypeptide from the thymosin family with immune activity and protective properties against oxidative stress induced by reactive oxygen species trimethylamine-N-oxide (TMAO), produced in the liver from gut bacterial metabolite trimethylamine and associated with increased cardiovascular disease risk and higher all-cause mortality. Ischemia-modified albumin (IMA) is a significant oxidative stress biomarker, particularly in ischemia-reperfusion conditions. This study investigates PTMα, TMAO, and IMA levels in type 2 diabetes mellitus (T2DM) patients, both with and without hyperlipidemia, to explore their relationships and their potential role as biomarkers or therapeutic targets. <b>Method:</b> The study received ethical approval from the Selcuk University Faculty of Medicine Hospital committee under approval number 2024/33. The study included male and female T2DM patients aged 30-60, with 30 having hyperlipidemia and the rest being non-lipemic. TMAO was performed using API 3200 LC-MS\\\\MS while PTMα was analyzed using an ELISA kit from BT LAB, serum IMA levels were evaluated by the spectrophotometric method. <b>Results:</b> Comparisons were made between those with T2DM and control groups. In the T2DM group, PTMα was significantly higher in females (<i>p</i> = 0.047), while TMAO and IMA showed no significant gender difference. The control group had no significant differences in PTMα, TMAO, and IMA levels. Comparisons among healthy controls, non-lipemic T2DM patients, and hyperlipidemic T2DM patients revealed significantly decreased PTMα levels with no change in IMA levels across groups. In contrast, TMAO was significantly higher in the patient group. <b>Conclusion:</b> The findings of this study have potential implications for the field, suggesting that PTMα might serve as a prognostic indicator for T2DM and that reduced TMAO levels might play a role in T2DM pathogenesis, opening up new avenues for research and treatment.</p>\",\"PeriodicalId\":53667,\"journal\":{\"name\":\"Qatar Medical Journal\",\"volume\":\"2025 2\",\"pages\":\"39\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337776/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Qatar Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5339/qmj.2025.39\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Qatar Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5339/qmj.2025.39","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
背景:原胸腺素α (PTMα)是胸腺素家族中的一种小酸性多肽,具有免疫活性和抗活性氧三甲胺- n -氧化物(TMAO)诱导的氧化应激的保护作用,由肠道细菌代谢物三甲胺在肝脏中产生,与心血管疾病风险增加和全因死亡率升高有关。缺血修饰白蛋白(IMA)是一种重要的氧化应激生物标志物,特别是在缺血再灌注条件下。本研究调查了伴有和不伴有高脂血症的2型糖尿病(T2DM)患者的PTMα、TMAO和IMA水平,探讨它们之间的关系及其作为生物标志物或治疗靶点的潜在作用。方法:本研究获得Selcuk大学医学院医院委员会的伦理批准,批准号为2024/33。该研究包括30-60岁的男性和女性2型糖尿病患者,其中30人患有高脂血症,其余无脂血症。用API 3200 LC-MS\MS检测TMAO,用BT LAB的ELISA试剂盒检测PTMα,用分光光度法测定血清IMA水平。结果:T2DM组与对照组进行比较。T2DM组PTMα在女性中显著升高(p = 0.047),而TMAO和IMA在性别上无显著差异。对照组PTMα、TMAO、IMA水平无显著差异。在健康对照组、非血脂型T2DM患者和高血脂型T2DM患者之间的比较显示,PTMα水平显著降低,各组间IMA水平无变化。相比之下,TMAO在患者组中显著升高。结论:本研究结果提示PTMα可能作为T2DM的预后指标,TMAO水平降低可能在T2DM发病机制中发挥作用,为T2DM的研究和治疗开辟了新的途径。
Evaluation of prothymosin alpha, trimethylamine-N-oxide, and ischemia-modified albumin in type 2 diabetes mellitus patients with dysregulated lipid profile.
Background: Prothymosin alpha (PTMα) is a small acidic polypeptide from the thymosin family with immune activity and protective properties against oxidative stress induced by reactive oxygen species trimethylamine-N-oxide (TMAO), produced in the liver from gut bacterial metabolite trimethylamine and associated with increased cardiovascular disease risk and higher all-cause mortality. Ischemia-modified albumin (IMA) is a significant oxidative stress biomarker, particularly in ischemia-reperfusion conditions. This study investigates PTMα, TMAO, and IMA levels in type 2 diabetes mellitus (T2DM) patients, both with and without hyperlipidemia, to explore their relationships and their potential role as biomarkers or therapeutic targets. Method: The study received ethical approval from the Selcuk University Faculty of Medicine Hospital committee under approval number 2024/33. The study included male and female T2DM patients aged 30-60, with 30 having hyperlipidemia and the rest being non-lipemic. TMAO was performed using API 3200 LC-MS\MS while PTMα was analyzed using an ELISA kit from BT LAB, serum IMA levels were evaluated by the spectrophotometric method. Results: Comparisons were made between those with T2DM and control groups. In the T2DM group, PTMα was significantly higher in females (p = 0.047), while TMAO and IMA showed no significant gender difference. The control group had no significant differences in PTMα, TMAO, and IMA levels. Comparisons among healthy controls, non-lipemic T2DM patients, and hyperlipidemic T2DM patients revealed significantly decreased PTMα levels with no change in IMA levels across groups. In contrast, TMAO was significantly higher in the patient group. Conclusion: The findings of this study have potential implications for the field, suggesting that PTMα might serve as a prognostic indicator for T2DM and that reduced TMAO levels might play a role in T2DM pathogenesis, opening up new avenues for research and treatment.